Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.

Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A, Kersten GF, van den Heuvel N, Hendriks JT, van der Pol LA.

Vaccine. 2011 Sep 22;29(41):7188-96. doi: 10.1016/j.vaccine.2011.05.079. Epub 2011 Jun 7.

PMID:
21651934
2.

Technology transfer of Sabin-IPV to new developing country markets.

Kreeftenberg H, van der Velden T, Kersten G, van der Heuvel N, de Bruijn M.

Biologicals. 2006 Jun;34(2):155-8. Epub 2006 May 2.

PMID:
16650773
3.

Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.

Verdijk P, Rots NY, Bakker WA.

Expert Rev Vaccines. 2011 May;10(5):635-44. doi: 10.1586/erv.11.51. Review.

PMID:
21604984
4.

Development of inactivated poliovirus vaccine from Sabin strains: A progress report.

Okayasu H, Sein C, Hamidi A, Bakker WA, Sutter RW.

Biologicals. 2016 Nov;44(6):581-587. doi: 10.1016/j.biologicals.2016.08.005. Epub 2016 Oct 5. Review.

PMID:
27720268
5.

Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.

Kersten G, Hazendonk T, Beuvery C.

Vaccine. 1999 Apr 9;17(15-16):2059-66.

PMID:
10217607
6.

Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.

Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WA.

Vaccine. 2013 Nov 12;31(47):5531-6. doi: 10.1016/j.vaccine.2013.09.021. Epub 2013 Sep 21.

PMID:
24063976
7.

CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.

Yang C, Shi H, Zhou J, Liang Y, Xu H.

Vaccine. 2009 Nov 5;27(47):6558-63. doi: 10.1016/j.vaccine.2009.08.047. Epub 2009 Sep 1.

PMID:
19729087
8.

Anomalous observations on IPV and OPV vaccination.

John TJ.

Dev Biol (Basel). 2001;105:197-208.

PMID:
11763328
9.

sIPV process development for costs reduction.

Thomassen YE, Bakker WA.

Vaccine. 2015 Aug 20;33(35):4307-12. doi: 10.1016/j.vaccine.2015.03.076. Epub 2015 Apr 6.

PMID:
25858858
10.

Rapid and accurate identification of poliovirus strains used for vaccine production.

Nijst OE, Mouthaan JJ, Mekkes DR, Jusic E, van der Avoort HG, Metz B.

J Virol Methods. 2013 Apr;189(1):189-95. doi: 10.1016/j.jviromet.2013.01.026. Epub 2013 Feb 19.

PMID:
23434540
11.
12.

Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals.

Thomassen YE, van 't Oever AG, van Oijen MG, Wijffels RH, van der Pol LA, Bakker WA.

PLoS One. 2013 Dec 12;8(12):e83374. doi: 10.1371/journal.pone.0083374. eCollection 2013.

13.

Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.

Taniuchi M, Famulare M, Zaman K, Uddin MJ, Upfill-Brown AM, Ahmed T, Saha P, Haque R, Bandyopadhyay AS, Modlin JF, Platts-Mills JA, Houpt ER, Yunus M, Petri WA Jr.

Lancet Infect Dis. 2017 Oct;17(10):1069-1079. doi: 10.1016/S1473-3099(17)30358-4. Epub 2017 Jul 7.

14.
15.

[Universal use of inactivated poliovirus vaccine--the needs and challenges].

Shimizu H, Takeda N.

Nihon Rinsho. 2008 Oct;66(10):1950-5. Review. Japanese.

PMID:
18939495
16.

Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba.

Resik S, Tejeda A, Fonseca M, Alemañi N, Diaz M, Martinez Y, Garcia G, Okayasu H, Burton A, Bakker WA, Verdijk P, Sutter RW.

Vaccine. 2014 Sep 22;32(42):5399-404. doi: 10.1016/j.vaccine.2014.07.109. Epub 2014 Aug 12.

PMID:
25131734
17.

Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.

Liao G, Li R, Li C, Sun M, Li Y, Chu J, Jiang S, Li Q.

J Infect Dis. 2012 Jan 15;205(2):237-43. doi: 10.1093/infdis/jir723. Epub 2011 Dec 8.

PMID:
22158682
18.

Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.

Asturias EJ, Dueger EL, Omer SB, Melville A, Nates SV, Laassri M, Chumakov K, Halsey NA.

J Infect Dis. 2007 Sep 1;196(5):692-8. Epub 2007 Jul 23.

PMID:
17674310
20.

Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.

Sanders BP, Oakes Ide L, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JH, Macadam A, Cello J, Edo-Matas D.

Vaccine. 2015 Nov 27;33(48):6611-6. doi: 10.1016/j.vaccine.2015.10.091. Epub 2015 Nov 1.

PMID:
26529068

Supplemental Content

Support Center